news details |
|
|
| ATLAS Group (Gwalior) eyes Indian Pharmaceutical market in a big way | | Launches a wide range of pharmaceuticals in Jammu & Kashmir | | Early Times Reporter
Srinagar | June 9
ATLAS Group (Gwalior) having diversified business interests in Bicycle, Steel & e-Bikes has now spread its wings into the burgeoning Indian Pharmaceuticals Industry under its new venture ATLAS Laboratories and Pharmaceuticals Ltd. With a mission to provide better quality medicine at highly affordable prices to the masses, ALPL today announced its entry into Jammu & Kashmir Market and has launched a wide range of medicine targeting mass market.
On the occasion, Ashwani Kapur, Executive Director, ATLAS Laboratories and Pharmaceuticals Ltd said, "Providing affordable medicine to mass market, reflects the ATLAS Group (Gwalior)'s long term commitment towards the common man and our foray into the pharmaceutical industry is also in line with the Indian government's policy of lowering down the drug prices; perhaps we are the only company who have initiated a step in this direction"
ALPL has set up one of the most advanced, state-of-the-art manufacturing plants in the country for manufacturing a gamut of pharmaceutical products, at SIDCUL Industrial Area, Hardwar, and Uttarakhand. The plant is designed as per World Health Organization (WHO) norms so as to meet export requirements and it also complies with all the International GMP Standards.
Disclosing the expansion plans of ALPL, Kapur said, "Ours is one of the largest integrated plants in Northern India, which provides almost all facilities under one roof. We have already invested over 100 crores in this plant and a further investment to the tune of 400-500 crores is in the pipeline." The company is targeting a top line of 500 crores in the next five years.
Some of the products in pipeline are Anti-Hypertensive, Anti-Anginal, Liver Formulation, Pro Biotic, Anti-Psychotic, Hormonal Preparations and Life-style drugs to be launched in the next phase. ALPL is also studying the market to launch life saving drugs in the Cardiovascular and Oncology segments.
Moreover, ALPL has plans to put up a large R&D facility for drug research & discovery in the next phase. It will also enter into collaborations with International companies to launch new molecules in India to provide advanced healthcare solutions to the Indian society."India has the potential to be the largest provider of economical cure for ailments, with the talent pool of skills, facilities and sensitivity to find solutions for the industry players as well as consumers", concluded Kapur. |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
 |
|
|
